Immunitybio Inc. (IBRX) Live Share Price, Invest From India

Immunitybio Inc. Stock Performance

as on October 25, 2025 at 1:29 am IST

Day's Low
Day's High
$2.42
Day's Price Range
$2.51
$2.46
1.63%
Downside
2.03%
Upside
52 Week's Low
52 Week's High
$1.83
52-Week Price Range
$7.48
$2.46
25.61%
Downside
204.07%
Upside

Immunitybio Inc. share price movements today

Previous Close: $2.39
Open: $2.45
Volume: 11.9M
Day's Low - High: $2.42 - $2.51
52 Week Low - High: $1.83 - $7.48

Immunitybio Inc. Historical Returns

1 Month Return: + 0.41 %
3 Month Return: -13.64 %
1 Year Return: -53.57 %
3 Year Return: -54.17 %
5 Year Return: 0 %

Immunitybio Inc. Stock Fundamentals & Key Indicators

Check Immunitybio Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.4B

EPS (TTM)

-0.4433

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-4.43

Industry PE ratio

8.355964912280701

PEG Ratio

EBITDA

-269.1M

Revenue (TTM)

56.6M

Profit Margin

0.00%

Return On Equity TTM

0.00%

Immunitybio Inc. Stock Valuation

Track how Immunitybio Inc. P/E has moved over time to understand its valuation trends.

Immunitybio Inc. in the last 5 years

Overview
Trends

Lowest (-34.68x)

March 31, 2021

Today (-4.43x)

October 25, 2025

Industry (8.36x)

October 25, 2025

Highest (-1.91x)

September 30, 2023

LowHigh

Today’s Price to Earnings Ratio: -4.43x

Immunitybio Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Immunitybio Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Immunitybio Inc.	BUY	$2.4B	NA	-4.43	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$60.9B	251.51%	-505.15	-12.96%
Beone Medicines Ltd	NA	$35.7B	NA	NA	-3.89%
Vertex Pharmaceuticals Incorporated	BUY	$109.3B	99.16%	30.04	31.86%
Regeneron Pharmaceuticals, Inc.	BUY	$62.0B	-0.32%	14.51	31.37%

Stock Returns calculator for Immunitybio Inc. Stock including INR - Dollar returns

The Immunitybio Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Immunitybio Inc. investment value today

Current value as on today

₹50,847

Returns

₹49,153

(-49.15%)

Returns from Immunitybio Inc. Stock

₹53,759 (-53.76%)

Dollar Returns*

₹4,606 (+4.61%)

Analyst Recommendation on Immunitybio Inc. Stock

Based on 8 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 8 analysts, 75% of analysts recommend a 'BUY' rating for Immunitybio Inc.. Average target price of $10.2

Immunitybio Inc. Share Price Target

Get share price movements and forecasts by analysts on Immunitybio Inc..

What analysts predicted

75.88%UPSIDE

Target Price

$10.2

Current Price

$2.46

Analyzed by

8 Analysts

Target

$10.20

Immunitybio Inc. target price $10.2, a slight upside of 75.88% compared to current price of $2.46. According to 8 analysts rating.

Immunitybio Inc. Stock’s Investor Sentiment and Interest

Investment in Immunitybio Inc. Shares on INDmoney has grown by 48.91% over the past 30 days, indicating increased transactional activity.

Time period: September 26, 2025 to October 26, 2025

Change:48.91% versus previous 30 day period

Search interest for Immunitybio Inc. Stock has decreased by -10% in the last 30 days, reflecting a downward trend in search activity.

Time period: September 26, 2025 to October 26, 2025

Change:-10% versus previous 30 day period

Immunitybio Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Total Revenue	0	0	0	0	0	1	6	7	16	26
Gross Profit	-5	-6	-4	-4	-4	1	6	7	16	26
Operating Income	-111	-85	-80	-84	-95	-99	-80	-69	-64	-71
EBITDA	-80	-99	-56	-196	-92	-91	-41	-17	-64	-59
Interest Expense	29	32	35	32	37	39	40	37	28	28
Depreciation	4	4	4	4	4	4	4	4	3	3
Income Before Tax	-116	-138	-95	-233	-134	-134	-85	-59	-129	-92
Income Tax Expense	34	20	-4	0	0	-4	-	0	-	0
Net Income	-151	-137	-95	-233	-134	-134	-85	-59	-129	-92
Net Profit Margin	-41989.44%	-336290.24%	-116563.41%	-167907.91%	-335272.50%	-12852.34%	-1404.01%	-783.40%	-784.92%	-350.26%

Immunitybio Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Revenue	0	0	0	0	2	0	0	0	0	14
Gross Profit	0	0	0	3	-6	-8	0	-23	0	14
Operating Income	-238	-124	-99	-98	-156	-220	-330	-351	-362	-344
EBITDA	-235	-117	-90	-86	-142	-187	-315	-335	-436	-241
Interest Expense	-	0	0	0	5	9	14	63	129	154
Depreciation	-	-	-	-	14	12	14	18	19	17
Income Before Tax	-237	-121	-96	-96	-160	-226	-349	-417	-583	-413
Income Tax Expense	0	0	0	0	0	-1	0	0	0	0
Net Income	-236	-120	-96	-96	-160	-224	-349	-417	-583	-413
Net Profit Margin	-100371.19%	-274565.91%	-214273.33%	-204736.17%	-7273.30%	-37055.70%	-37456.96%	-173883.33%	-93761.41%	-2804.77%

Immunitybio Inc. Quarterly Cash Flow

All numbers in Millions USD

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Net Income	-138	-95	-233	-134	-134	-85	-59	-129	-92
Operating Cash Flow	-79	-87	-115	-106	-100	-98	-85	-85	-79
Investing Cash Flow	-8	-15	2	-35	-51	65	9	4	-16
Financing Cash Flow	43	237	200	10	148	15	106	0	172
Change in Cash	-44	134	87	-132	-2	-18	31	-82	76

Immunitybio Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Net Income	-120	-96	-96	-160	-224	-349	-417	-583	-413
Operating Cash Flow	-38	-48	-63	-152	-171	-274	-337	-366	-391
Investing Cash Flow	-113	99	57	18	-19	-84	27	-30	-12
Financing Cash Flow	-15	-34	0	114	150	505	233	558	281
Change in Cash	-167	15	-7	-19	-40	146	-76	160	-121

Global Institutional Holdings in Immunitybio Inc.

Funds	Holdings
Vanguard Group Inc	2.31%
BlackRock Inc	1.88%
Bank of America Corp	0.93%
Armistice Capital, LLC	0.82%
Jane Street Group LLC	0.82%

See all

Insights on Immunitybio Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, -129.64M → -92.55M (in $), with an average increase of 40.1% per quarter
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 6 quarters, 40.0K → 26.42M (in $), with an average increase of 58.0% per quarter
NO EFFECT
Against Peers
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.7% return, outperforming this stock by 116.3%
NO EFFECT
Against Peers
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 130.5% return, outperforming this stock by 185.6%
NEGATIVE IMPACT
Price Dip
In the last 1 year, IBRX stock has moved down by -53.6%

About Immunitybio Inc.

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer (‘nk’) and t cells, tumoricidal macrophages, and memory t cells.

Organisation	Immunitybio Inc.
Headquarters	3530 John Hopkins Court, San Diego, CA, United States, 92121
Industry	Healthcare
CEO	Mr. Richard Gerald Adcock
E-voting on shares	Click here to vote

Key Management of Immunitybio Inc.

Name	Title
Ms. Regan J. Lauer	Chief Accounting Officer
Dr. Enrique Diloné Ph.D., RAC	Chief Technology Officer
Ms. Sarah Singleton	Chief Communications Officer & Head of Patient Advocacy
Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., M.Sc.	Executive Chairman of the Board and Global Chief Scientific & Medical Officer
Mr. David C. Sachs	Chief Financial Officer
Dr. Barry J. Simon M.D.	Chief Corporate Affairs Officer & Director
Dr. Sandeep K. Reddy M.D.	Chief Medical Officer
Mr. Richard Gerald Adcock	President, CEO & Director
Mr. Jason R. Liljestrom J.D.	General Counsel & Corporate Secretary
Dr. Leonard S. Sender M.D.	Chief Medical Officer of Liquid Tumors & Cell Therapy

FAQs

What is Immunitybio Inc. share price today?

Immunitybio Inc. share price today is $2.46 as on October 25, 2025 at 1:29 am IST at the close of the market. Immunitybio Inc. share today touched a day high of $2.51 and a low of $2.42.

What is the 52 week high and 52 week low for Immunitybio Inc. share?

Immunitybio Inc. share touched a 52 week high of $7.48 on October 25, 2024 and a 52 week low of $1.83 on May 7, 2025. Immunitybio Inc. stock price today i.e. October 25, 2025 at 1:29 am IST is closed at $2.46,which is 67.11% down from its 52 week high and 34.43% up from its 52 week low.

What is Immunitybio Inc.'s market capitalisation today?

Immunitybio Inc. market capitalisation is $0.00T as on October 25, 2025 at 1:29 am IST.

How to invest in Immunitybio Inc. Stock (IBRX) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Immunitybio Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Immunitybio Inc. Shares that will get you 0.6098 shares as per Immunitybio Inc. share price of $2.46 per share as on October 25, 2025 at 1:29 am IST.

What is the minimum amount required to buy Immunitybio Inc. Stock (IBRX) from India?

Indian investors can start investing in Immunitybio Inc. (IBRX) shares with as little as ₹87.796 or $1 (as of October 26, 2025 at 10:42 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹877.96 in Immunitybio Inc. stock (as per the Rupee-Dollar exchange rate as on October 26, 2025 at 10:42 am IST). Based on Immunitybio Inc. share’s latest price of $2.46 as on October 25, 2025 at 1:29 am IST, you will get 4.0650 shares of Immunitybio Inc.. Learn more about fractional shares .